3 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 3 of 3 clinical reviews.
Flibanserin (Addyi) is FDA-approved only for premenopausal adults. This clinical guide covers the evidence gaps, safety concerns, and regulatory context for any off-label consideration in adolescents ages 12 to 17.
A guide to flibanserin (Addyi) use in geriatric patients aged 65 and older, covering pharmacokinetics, safety, alcohol interaction, dose management, and transition-of-care planning for women moving from reproductive to post-reproductive care.
Flibanserin (Addyi) is not approved for children under 12. This clinical guide explains the FDA approval scope, CNS sedation risks relevant to school performance, and what parents and clinicians should know about activity restrictions.